Companies
/
Mammoth Biosciences
Healthtech
Mammoth Biosciences is a South San Francisco-based biotechnology company developing CRISPR-based gene editing and diagnostic technologies, co-founded by CRISPR pioneer Jennifer Doudna.
$831M
+$7.26
924.55%
30 days ago
$0.78
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Sign up with Augment to see the latest market activity.
Mammoth Biosciences was founded in 2017 by Trevor Martin, Janice Chen, Lucas Harrington, and Jennifer Doudna, the latter a biochemist who shared the 2020 Nobel Prize in Chemistry for her foundational co-discovery of CRISPR gene editing technology, positioning Mammoth to work at the cutting edge of applying and extending CRISPR-based tools for both diagnostic and therapeutic applications. CRISPR technology, broadly, allows scientists to precisely target and edit specific sequences of DNA, and Mammoth has focused particularly on identifying and engineering novel CRISPR proteins beyond the most commonly used Cas9 system, including smaller and more versatile CRISPR variants that the company argues can expand the range of practical applications for CRISPR-based technology, including applications not well suited to the original, more widely known Cas9 system. The company has pursued two primary application areas for its CRISPR technology platform: diagnostics, including rapid, low-cost detection tests that use CRISPR's precise DNA and RNA-targeting capability to detect the presence of specific pathogens or genetic markers, technology the company advanced significantly during the COVID-19 pandemic in developing CRISPR-based diagnostic tests for the virus; and therapeutics, pursuing gene editing-based treatments for genetic diseases, an area where Mammoth has both pursued its own internal therapeutic development programs and licensed its CRISPR technology platform to pharmaceutical partners for their own therapeutic development efforts. Mammoth has built partnerships with major pharmaceutical and biotechnology companies seeking to license its novel CRISPR systems for their own drug development programs, positioning the company as both a therapeutic developer in its own right and a platform technology licensor to the broader gene editing and genomic medicine industry, a common dual-track strategy among foundational biotechnology platform companies seeking to balance the significant capital requirements and long timelines of independent drug development against nearer-term revenue from technology licensing and partnership deals. The company has raised substantial venture funding from investors including Mayfield, NFX, and Redmile Group, reaching a valuation exceeding $1 billion.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
